Showing results (651-660 of 857) with videos related to
Sort By:
Pageof 86
Frontiers in Immunology|March 30, 2026
Molecular determinants of STEC-HUS: from complement activation to microvascular thrombosisDonata Santarsiero, Miriam Galbusera, Sara Gastoldi, et al.Kidney International|February 10, 2012
Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injuryPaola Cassis, Lorenzo Gallon, Ariela Benigni, et al.Diabetes|June 5, 2013
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapyErica Rurali, Marina Noris, Antonietta Chianca, et al.Blood Advances|December 1, 2021
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19Sistiana Aiello, Sara Gastoldi, Miriam Galbusera, et al.Transplantation|February 24, 2007
DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic propertiesSistiana Aiello, Paola Cassis, Linda Cassis, et al.Transplantation|November 9, 2007
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injuryPiero Ruggenenti, Norberto Perico, Eliana Gotti, et al.Clinical Journal of the American Society of Nephrology : CJASN|November 14, 2008
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndromeJeffrey M Saland, Benjamin L Shneider, Jonathan S Bromberg, et al.Frontiers in Immunology|July 7, 2025
C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patientsValeria Guaschino, Donata Santarsiero, Sara Gastoldi, et al.Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.BMJ Open|September 26, 2019
Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE)Marvin Gonzalez-Quiroz, Dorothea Nitsch, Sophie Hamilton, et al.Pageof 86